latest news releases from the newsroom
VuBotics Announces Election of Marc Owensby to Board of Directors
ATLANTA, Aug. 22, 2007 (PRIME NEWSWIRE) -- VuBotics, Inc. (OTCBB:VBTC), developer of VuIT(tm), the global leader in small screen reading technology, today announced the election of Marc Owensby to its board of directors. Mr. Owensby will join the company's chairman and CEO, Philip Lundquist, as well as Robert Eramian and Ronan Harris, increasing the board to 4 members. Mr. Owensby brings extensive international mobile telecommunications industry expertise and emerging growth company experience.
Pride International, Inc.
Pride International, Inc. Acquires Remaining Interest in Angolan Joint Venture
HOUSTON, Aug. 22, 2007 (PRIME NEWSWIRE) -- Pride International, Inc. (NYSE:PDE) today announced that it has acquired the remaining nine percent interest in its Angolan joint venture company from a subsidiary of Sonangol, the national oil company of Angola. The joint venture owns the two deepwater drillships Pride Africa and Pride Angola and the 300 ft. independent-leg jackup rig Pride Cabinda, and holds management agreements for the deepwater platform rigs Kizomba A and Kizomba B. The acquisition increases Pride's ownership in the three mobile offshore drilling units and the two management agreements, along with related working capital, to 100 percent. Cash consideration in the transaction of $45 million was paid with cash on hand and borrowings under the company's revolving credit facility.
Talon Therapeutics, Inc.
Hana Biosciences Receives Fast Track Designation for Marqibo for the Treatment of Relapsed Acute Lymphoblastic Leukemia
SOUTH SAN FRANCISCO, Calif., Aug. 22, 2007 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on advancing cancer care, today announced that Marqibo(r) (vincristine sulfate injection, OPTISOME(tm)) has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with Philadelphia chromosome negative acute lymphoblastic leukemia (ALL) in second relapse or who have failed two lines of prior therapy. Earlier this year, Marqibo was also granted Orphan Drug Designation by the FDA for the treatment of adult ALL.
Emily Tan Media Relations
Bliss Lounge in Clifton, NJ Hosts 'Bobby Czyz Night' to Benefit Boxing Champ
CLIFTON, N.J., Aug. 22, 2007 (PRIME NEWSWIRE) -- Boxing champ, Bobby Czyz, is a fighter down to the last cell in his body. He's a prize fighter, but on a molecular level as well as in the ring. After having survived a horrific car crash -- where Czyz and his bodyguard/friend of 30 years were passengers in the latter's Mercedes-Benz in April of 2007, driven by an associate of the bodyguard, a crash more devastating than suffered in any professional bout -- Czyz cheated death and lived not only to walk away from his near-death injuries, but to triumph over them as stunned physicians had never before witnessed.
Generex Biotechnology Corp.
Generex Biotechnology to Collaborate With Leading Investigator At the Univerity of Rochester On Pandemic Avian Influenza Vaccine
WORCESTER, Mass., Aug. 22, 2007 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) announced today that its wholly-owned immunotherapy subsidiary, Antigen Express, Inc., has entered into an agreement with the University of Rochester as part of the Antigen Express efforts to develop a novel vaccine against the potentially pandemic avian influenza. The collaboration brings together Dr. John Treanor, an internationally recognized leader in the clinical development of pandemic influenza vaccines, and the novel peptide vaccine technology pioneered by Antigen Express. Dr. Treanor is Professor of Medicine, and of Microbiology and Immunology, in the Department of Medicine at the University of Rochester Medical Center.